Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris

NACompletedINTERVENTIONAL
Enrollment

394

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Inflammatory Acne Vulgaris
Interventions
DEVICE

Sebacia microparticles and laser

DEVICE

Vehicle suspension and laser

DEVICE

Sebacia microparticles without laser

Trial Locations (19)

17033

Penn State Hershey Medical Center, Hershey

19067

Yardley Dermatology Associates, Yardley

21030

Maryland Laser, Skin & Vein Institute, Hunt Valley

28207

Dermatology, Laser & Vein Specialists of the Carolinas, Charlotte

29414

Dermatology & Laser Center of Charleston, Charleston

30078

Gwinnett Dermatology, PC, Snellville

33173

Miami Dermatology & Laser Institute, Miami

33716

Spencer Dermatology, St. Petersburg

37215

Tennessee Clinical Research Center, Nashville

46032

Shideler Clinical Research Center, Carmel

48346

Clarkston Skin Research, Clarkston

60563

The Dermatology Institute-DuPage Medical Group, Naperville

78660

Austin Institute for Clinical Research, Pflugerville

85255

Clear Dermatology & Aesthetics Center, Scottsdale

89144

James Q Del Rosso, DO, LLC, Las Vegas

92204

Spokane Dermatology Clinic, Spokane

95816

Laser & Skin Surgery Center of Northern California, Sacramento

95819

Center for Dermatology & Laser Surgery, Sacramento

07601

Skin Laser & Surgery Specialists of NY & NJ, Hackensack

All Listed Sponsors
lead

Sebacia, Inc.

INDUSTRY

NCT02217228 - Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris | Biotech Hunter | Biotech Hunter